IntegriChain Appoints Chris Hare Chief Revenue Officer
The healthcare commercialization platform adds the former Intelerad executive to its senior leadership team.
Updated on Oct. 28, 2026 in Healthcare

Live Poll
Do you believe hiring external executives is the best way for established companies to grow?
Philadelphia-based IntegriChain has appointed Chris Hare as its new chief revenue officer. Hare joins the company as it enters its 20th year of operations.
Why it matters
The appointment brings significant leadership experience to the firm as it continues to expand its role in managing the financial and operational dimensions of drug access.
IntegriChain currently maintains a workforce of over 700 employees and is marking 20 years in business. This follows a majority share acquisition by Nordic Capital in November 2023.
The players
IntegriChain
This Philadelphia-based company provides a commercialization platform that connects commercial, financial, and operational dimensions of drug access and profitability.
Chris Hare
He is the new chief revenue officer for IntegriChain who previously held leadership roles at Intelerad Medical Systems, Net Health, Rhinogram, and Miraca Life Sciences.
Nordic Capital
This private equity firm acquired a majority share of IntegriChain in November 2023.
GE Healthcare
This global medical technology company acquired Intelerad Medical Systems for $2.3 billion in April 2026.
The details
Hare previously spent over two years as chief revenue and growth officer at Intelerad Medical Systems, which was sold to GE Healthcare for $2.3 billion in April 2026. He will operate from his base in Nashville while supporting the Philadelphia-headquartered company.
Timeline
Nordic Capital acquired a majority share of IntegriChain in November 2023.
Intelerad Medical Systems was sold to GE Healthcare in April 2026.
IntegriChain hired Chris Hare in October 2026.
Market Landscape
This leadership addition follows the majority share acquisition by Nordic Capital in 2023. The firm is positioning itself for continued scale within the competitive drug commercialization and financial consulting sector.
For customers and partners, the executive change signifies a focus on long-term growth and stability for the company's consulting and platform services. No changes to existing service contracts or product availability have been announced.
The takeaway
The move demonstrates how firms under private equity ownership often prioritize senior executive additions to drive revenue growth. Companies in this space are increasingly leveraging high-level leadership experience to navigate complex drug access and pricing markets.
Further reading
For more on industry developments, visit the Healthcare section.
Source note: This article includes information reported by Consulting.
Live Poll
Do you believe hiring external executives is the best way for established companies to grow?









